Mohsin Shafiq

Dr. Mohsin Shafiq

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in Science Advances
Verified
Journal Article
Open access
LLLuise Linsenmeier
Luise Linsenmeier
BMBehnam Mohammadi
Behnam Mohammadi
MSMohsin Shafiq
Mohsin Shafiq
KFKarl Frontzek
Karl Frontzek
JBJulia Bär
Julia Bär
MGMarkus Glatzel
Markus Glatzel
Ligand-stimulated enzymatic release or cellular degradation of PrP may interfere with neurodegeneration-associated toxicity.

7 November 2024 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
AMAndreu Matamoros‐Angles
Andreu Matamoros‐Angles
EKEmina Karadjuzovic
Emina Karadjuzovic
BMBehnam Mohammadi
Behnam Mohammadi
FSFeizhi Song
Feizhi Song
SBSantra Brenna
Santra Brenna
MGMarkus Glatzel
Markus Glatzel
Extracellular vesicles (EVs) have gained significant attention as pathology mediators and potential diagnostic tools for neurodegenerative diseases. However, isolation of brain‐derived EVs (BDEVs) from tissue remains challenging, often involving enzymatic digestion steps that may compromise the integrity of EV proteins and overall functionality. Here, we describe that collagenase digestion, commonly used for BDEV isolation, produces undesired protein cleavage of EV‐associated proteins in brain tissue homogenates and cell‐derived EVs. In order to avoid this effect, we studied the possibility of isolating BDEVs with a reduced amount of collagenase or without any protease. Characterization of the isolated BDEVs from mouse and human samples (both female and male) revealed their characteristic morphology and size distribution with both approaches. However, we show that even minor enzymatic digestion induces ‘artificial’ proteolytic processing in key BDEV markers, such as Flotillin‐1, CD81, and the cellular prion protein (PrP C ), whereas avoiding enzymatic treatment completely preserves their integrity. We found no major differences in mRNA and protein content between non‐enzymatically and enzymatically isolated BDEVs, suggesting that the same BDEV populations are purified with both approaches. Intriguingly, the lack of Golgi marker GM130 signal, often referred to as contamination indicator (or negative marker) in EV preparations, seems to result from enzymatic digestion rather than from its actual absence in BDEV samples. Overall, we show that non‐enzymatic isolation of EVs from brain tissue is possible and avoids artificial pruning of proteins while achieving an overall high BDEV yield and purity. This protocol will help to understand the functions of BDEV and their associated proteins in a near‐physiological setting, thus opening new research approaches.

26 June 2017 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
SZSaima Zafar
Saima Zafar
MSMohsin Shafiq
Mohsin Shafiq
NYNeelam Younas
Neelam Younas
MSMatthias Schmitz
Matthias Schmitz
IFIsidre Ferrer
Isidre Ferrer
IZInga Zerr
Inga Zerr
Rapidly progressive Alzheimer’s disease (rpAD) is a variant of AD distinguished by a rapid decline in cognition and short disease duration from onset to death. While attempts to identify rpAD based on biomarker profile classifications have been initiated, the mechanisms which contribute to the rapid decline and prion mimicking heterogeneity in clinical signs are still largely unknown. In this study, we characterized prion protein (PrP) expression, localization, and interactome in rpAD, slow progressive AD, and in non-dementia controls. PrP along with its interacting proteins were affinity purified with magnetic Dynabeads Protein-G, and were identified using Q-TOF-ESI/MS analysis. Our data demonstrated a significant 1.2-fold decrease in di-glycosylated PrP isoforms specifically in rpAD patients. Fifteen proteins appeared to interact with PrP and only two proteins3/4histone H2B-type1-B and zinc alpha-2 protein3/4were specifically bound with PrP isoform isolated from rpAD cases. Our data suggest distinct PrP involvement in association with the altered PrP interacting protein in rpAD, though the pathophysiological significance of these interactions remains to be established.

14 January 2016 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SZSaima Zafar
Saima Zafar
NYNeelam Younas
Neelam Younas
SCSusana Correia
Susana Correia
MSMohsin Shafiq
Mohsin Shafiq
WTWaqas Tahir
Waqas Tahir
IZInga Zerr
Inga Zerr

4 May 2020 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
BMBehnam Mohammadi
Behnam Mohammadi
LLLuise Linsenmeier
Luise Linsenmeier
MSMohsin Shafiq
Mohsin Shafiq
Berta PuigBerta Puig
Berta Puig
GGGiovanna Galliciotti
Giovanna Galliciotti
HAHermann Altmeppen
Hermann Altmeppen
The structurally disordered N-terminal half of the prion protein (PrPC) is constitutively released into the extracellular space by an endogenous proteolytic cleavage event. Once liberated, this N1 fragment acts neuroprotective in ischemic conditions and interferes with toxic peptides associated with neurodegenerative diseases, such as amyloid-beta (Aβ) in Alzheimer’s disease. Since analog protective effects of N1 in prion diseases, such as Creutzfeldt-Jakob disease, have not been studied, and given that the protease releasing N1 has not been identified to date, we have generated and characterized transgenic mice overexpressing N1 (TgN1). Upon intracerebral inoculation of TgN1 mice with prions, no protective effects were observed at the levels of survival, clinical course, neuropathological, or molecular assessment. Likewise, primary neurons of these mice did not show protection against Aβ toxicity. Our biochemical and morphological analyses revealed that this lack of protective effects is seemingly due to an impaired ER translocation of the disordered N1 resulting in its cytosolic retention with an uncleaved signal peptide. Thus, TgN1 mice represent the first animal model to prove the inefficient ER translocation of intrinsically disordered domains (IDD). In contrast to earlier studies, our data challenge roles of cytoplasmic N1 as a cell penetrating peptide or as a potent “anti-prion” agent. Lastly, our study highlights both the importance of structured domains in the nascent chain for proteins to be translocated and aspects to be considered when devising novel N1-based therapeutic approaches against neurodegenerative diseases.

11 July 2015 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Franc LlorensFranc Llorens
Franc Llorens
NKNiels Kruse
Niels Kruse
MSMatthias Schmitz
Matthias Schmitz
MSMohsin Shafiq
Mohsin Shafiq
JCJosé Eriton Gomes da Cunha
José Eriton Gomes da Cunha
IZInga Zerr
Inga Zerr